Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib and Dalpiciclib Neoadjuvant Therapy for HR+ HER2-low Breast Cancer
NCT07189884Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of pyrotinib, dalpiciclib in breast cancer, sponsored by First Affiliated Hospital of Xiamen University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
pyrotinibdalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07189884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189884.